Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - hypertonie - herz-kreislauf-system - behandlung der essentiellen hypertonie bei erwachsenen:nehmen sie an therapyonduarp ist indiziert bei erwachsenen, deren blutdruck nicht ausreichend kontrolliert auf amlodipin. ersatz therapyadult patienten, die telmisartan und amlodipin von separaten tabletten erhalten stattdessen onduarp tabletten enthalten die gleiche komponente dosen.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

cis bio gmbh (8092467) - fludeoxyglucose ((18)f) - injektionslösung - teil 1 - injektionslösung; fludeoxyglucose ((18)f) (24991) information nicht vorhanden

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

takeda pharmaceuticals international ag t/a takeda pharmaceuticals international ag ireland branch (1009404) - lisdexamfetamindimesilat - hartkapsel - 70 mg - teil 1 - hartkapsel; lisdexamfetamindimesilat (37246) 70 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

takeda pharmaceuticals international ag t/a takeda pharmaceuticals international ag ireland branch (1009404) - lisdexamfetamindimesilat - hartkapsel - 50 mg - teil 1 - hartkapsel; lisdexamfetamindimesilat (37246) 50 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

takeda pharmaceuticals international ag t/a takeda pharmaceuticals international ag ireland branch (1009404) - lisdexamfetamindimesilat - hartkapsel - 30 mg - teil 1 - hartkapsel; lisdexamfetamindimesilat (37246) 30 milligramm

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

pharmaselect international beteiligungs gmbh - flumazenil - flumazenil

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

cis bio gmbh (8092467) - natriumiodid ((131)i) - injektionslösung - teil 1 - injektionslösung; natriumiodid ((131)i) (15340) information nicht vorhanden

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

cis bio gmbh (8092467) - ((201)tl)thallium(i)-chlorid - injektionslösung - teil 1 - injektionslösung; ((201)tl)thallium(i)-chlorid (15604) 37 megabecquerel

Europäische Union - Deutsch - EMA (European Medicines Agency)

gilead sciences international ltd  - emtricitabine, rilpivirine hydrochloride, tenofovir disoproxil fumarate - hiv-infektionen - antivirale mittel zur systemischen anwendung - eviplera ist indiziert zur behandlung von erwachsenen mit humanen immundefizienz-virustyp 1 (hiv-1) ohne bekannten mutationen resistenz gegen nicht-nukleosid-reverse-transkriptase-inhibitoren (nnrti)-klasse, tenofovir und emtricitabin infiziert, und mit einer viralen belastung ≤ 100.000 hiv-1-rna kopien/ml. wie bei anderen antiretroviralen arzneimitteln sollten genotypische resistenztests und / oder historische resistenzdaten die verwendung von eviplera leiten.

Europäische Union - Deutsch - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - hiv-infektionen - antivirale mittel zur systemischen anwendung - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.